Literature DB >> 21529744

Effectiveness and safety of the genous endothelial progenitor cell-capture stent in acute ST-elevation myocardial infarction.

Adrian F Low1, Chi-Hang Lee, Swee-Guan Teo, Mark Y Chan, Edgar Tay, Yian-Ping Lee, Eric Chong, Melissa Co, Eduardo Tin Hay, Yean-Teng Lim, Huay-Cheem Tan.   

Abstract

The endothelial progenitor cell (EPC)-capture stent promotes endothelialization and preliminary studies have suggested its safety and feasibility in ST-elevation myocardial infarction (STEMI). Detailed late clinical follow-up and angiographic analyses are, however, limited. We sought to determine late angiographic and clinical outcomes of the Genous EPC-capture stent in primary angioplasty. EPC-capture stents were implanted during primary angioplasty in 489 consecutive patients presenting with STEMI from 2004 through 2008. The first 100 consenting patients undergoing successful stent implantation scheduled to undergo relook coronary angiography at 6 to 12 months were enrolled. Ninety-five patients with 96 lesions were analyzed independently. Mean duration of follow-up coronary angiography was 245 days. In-stent late luminal loss measured 0.87 ± 0.67 mm. Binary restenosis (defined as >50% diameter stenosis) was 28%, with diffuse in-stent restenosis (Mehran class II) as the predominant pattern. Of 27 patients with binary restenosis, 14 (52%) were symptomatic, with 10 patients undergoing target lesion revascularization. Asymptomatic patients had significantly larger reference vessel and in-stent minimal luminal diameters (2.77 ± 0.39 vs 2.54 ± 0.44 mm, p = 0.040; 2.74 ± 0.34 vs 2.31 ± 0.72 mm, p = 0.004, respectively). Follow-up late loss and diameter stenoses were also in favor of the asymptomatic group. Major adverse cardiac event rate was 16% at a mean follow-up of 34 months. There were no cases of Academic Research Consortium-defined stent thrombosis. In conclusion, implantation of the EPC-capture stent during primary angioplasty is associated with a favorable late clinical outcome but with higher than anticipated angiographic late loss.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21529744     DOI: 10.1016/j.amjcard.2011.03.024

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Endothelial progenitor cells in cardiovascular diseases.

Authors:  Poay Sian Sabrina Lee; Kian Keong Poh
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

2.  Severe obstructive sleep apnea and outcomes following myocardial infarction.

Authors:  Chi-Hang Lee; See-Meng Khoo; Mark Y Chan; Hwee-Bee Wong; Adrian F Low; Qian-Hui Phua; A Mark Richards; Huay-Cheem Tan; Tiong-Cheng Yeo
Journal:  J Clin Sleep Med       Date:  2011-12-15       Impact factor: 4.062

3.  Study of novel coating strategy for coronary stents: simutaneous coating of VEGF and anti- CD34 antibody.

Authors:  Chun-Li Song; Qian Li; Yun-Peng Yu; Guan Wang; Jin-Peng Wang; Yang Lu; Ji-Chang Zhang; Hong-Ying Diao; Jian-Gen Liu; Yi-Hang Liu; Jia Liu; Ying Li; Dan Cai; Bin Liu
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Mar-Apr

4.  9-year clinical follow-up of patients with ST-segment elevation myocardial infarction with Genous or TAXUS Liberté stents.

Authors:  Georgiana-Aura Giurgea; Andrea Heuberger; Jamil Babayev; Susanne Winkler; Oliver Schlager; Irene M Lang; Mariann Gyöngyösi
Journal:  PLoS One       Date:  2018-08-06       Impact factor: 3.240

Review 5.  The State of Art of Regenerative Therapy in Cardiovascular Ischemic Disease: Biology, Signaling Pathways, and Epigenetics of Endothelial Progenitor Cells.

Authors:  Fabio Perrotta; Angelica Perna; Klara Komici; Ersilia Nigro; Mariano Mollica; Vito D'Agnano; Antonio De Luca; Germano Guerra
Journal:  Cells       Date:  2020-08-11       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.